Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
Nasdaq6d
Corbus Pharmaceuticals Presents Promising Phase 1 Dose-Escalation Study Findings for CRB-701 at ASCO GU 2025
Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...
Nasdaq6d
Corbus Presents CRB-701 Phase 1 Data With Promising Efficacy In Multiple Tumor Types At ASCO
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc.(CRBP), has reported promising data for CRB-701 or SYS6002, a next-generation Nectin-4 targeting antibody-drug conjugate or ADC, at the 2025 ...
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...
STAT6d
Corbus reports first Western data for closely tracked ADC cancer drug
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Corbus Pharmaceuticals falls after trial data for lead asset
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
The Pharma Letter3d
Investors unsure on Corbus data for potential Padcev rival
Corbus earlier announced the presentation of data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 (SYS6002) at the 2025 American Society of Clinical Oncology ...
Benzinga.com6d
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
CRB-701 shows 4% combined peripheral neuropathy rate across studies, with no dose-limiting toxicities reported in the dose escalation phase. A proactive ocular toxicity protocol in the Western ...